Results 141 to 150 of about 62,398 (280)

Epidemiology and Genetics of Rheumatic Diseases Suggest a Constant Rate of DNA Damage as Underlying Cause

open access: yesImmunology, Volume 177, Issue 4, Page 736-748, April 2026.
A constant rate of DNA damage that is not perfectly repaired will cause a constant rate of DNA mutations. The chance of mutation will increase if DNA is prone to damage, such as occurs in somatic hypermutation (SHM) hotspots and GC‐rich DNA. Thus, if one mutation‐prone DNA site drives disease, the age of onset of disease and degree of penetrance should
Piet C. de Groen
wiley   +1 more source

Clinicopathological features of graft versus host disease‐associated myositis

open access: yesAnnals of Clinical and Translational Neurology
Background and Objective Chronic graft versus host disease (GVHD)‐associated myositis targeting skeletal muscle is a relatively rare but potentially debilitating complication following allogeneic hematopoietic stem cell transplantation (HSCT).
Tomoyuki Kazuta   +10 more
doaj   +1 more source

Sharing Is Caring?—Pathogens and Pathogen‐Specific Antibodies in Arctic Endemic Seal Species and the Newly Sympatric Harbor Seals in Kongsfjorden, Svalbard

open access: yesMarine Mammal Science, Volume 42, Issue 2, April 2026.
ABSTRACT Climate change associated transformations of Arctic marine ecosystems are having detrimental impacts on Arctic endemic marine mammals. However, warming conditions are providing new habitats for temperate marine mammals, some of which are expanding into Arctic regions, posing a threat of novel pathogen introduction and disease transmission.
Luca A. Schick   +11 more
wiley   +1 more source

Enfortumab vedotin plus pembrolizumab in treatment‐naïve metastatic urothelial carcinoma patients: An Austrian real‐world analysis

open access: yesInternational Journal of Cancer, Volume 158, Issue 6, Page 1654-1665, 15 March 2026.
What's new? New antibody‐drug conjugates (ADCs) and immunotherapies have helped expand treatment options for urothelial carcinoma (UC). Clinical trials suggest that the ADC enfortumab vedotin (EV) and the immunotherapeutic agent pembrolizumab, when used in combination, are especially effective against UC.
Dora Niedersuess‐Beke   +30 more
wiley   +1 more source

Insights Into the Antigenic Repertoire of Unclassified Synaptic Antibodies

open access: yesAnnals of Clinical and Translational Neurology, Volume 13, Issue 3, Page 547-561, March 2026.
ABSTRACT Objective We sought to characterize the sixth most common finding in our neuroimmunological laboratory practice (tissue assay‐observed unclassified neural antibodies [UNAs]), combining protein microarray and phage immunoprecipitation sequencing (PhIP‐Seq). Methods Patient specimens (258; 133 serums; 125 CSF) meeting UNA criteria were profiled;
Michael Gilligan   +22 more
wiley   +1 more source

The feature and significance of lower limb MRI in adult myositis patients with anti-NXP2 antibody: a retrospective cohort study in China

open access: yesFrontiers in Medicine
ObjectiveThis study aimed to describe the MRI features of lower limbs (thighs and calves) in patients with anti-NXP2 antibody positive myositis, and explore their relationship with clinical manifestations and prognosis.MethodsAdult patients with anti ...
Li Shanshan   +5 more
doaj   +1 more source

Prevalence, Determinants, and Outcomes of Low Disease Activity and Remission Attainment in Patients With Systemic Lupus Erythematosus That Is Clinically Active

open access: yesArthritis Care &Research, Volume 78, Issue 3, Page 378-387, March 2026.
Objective This study aimed to identify in patients with systemic lupus erythematosus (SLE) with clinically active disease the attainment of frequency and determinants of Lupus Low Disease Activity State (LLDAS) and Definition of Remission in SLE (DORIS) and the frequency and determinants of flare and damage accrual after target attainment.
Yanjie Hao   +39 more
wiley   +1 more source

Myositis-specific and myositis-associated autoantibodies: their clinical characteristics and potential pathogenic roles

open access: yesImmunological Medicine
In recent years, various myositis-specific and myositis-associated autoantibodies have been identified in idiopathic inflammatory myopathies, including dermatomyositis (DM), anti-synthetase syndrome (ASS), immune-mediated necrotizing myopathy (IMNM), and
Mariko Ogawa-Momohara, Yoshinao Muro
doaj   +1 more source

Distinct by Design: Unraveling the Unique Clinical and Transcriptomic Identity of Juvenile Scleromyositis Overlap Compared to Juvenile Systemic Sclerosis and Juvenile Dermatomyositis: Implications for Care and Pathogenesis

open access: yesACR Open Rheumatology, Volume 8, Issue 3, March 2026.
Objective To characterize clinical and transcriptomic differences in juvenile scleromyositis overlap (jOverlap) compared to juvenile systemic sclerosis (jSSc) and juvenile dermatomyositis (JDM), focusing on autoantibody profiles, organ involvement, treatment, and peripheral blood gene expression.
Amanda D. Robinson   +6 more
wiley   +1 more source

Myositis ossificans [PDF]

open access: yesMedical Journal Armed Forces India, 2012
openaire   +2 more sources

Home - About - Disclaimer - Privacy